NowRx, Inc.
Securities Class Action Lawsuit
Class Period: February 1, 2022 – November 5, 2022
What Is the NowRx, Inc. Class Action Lawsuit About?
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NowRx, Inc. (‘NowRx”) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired NowRx securities between February 1, 2022, and November 5, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.
NowRx Case Details
The Complaint alleges that NowRx and other defendants failed to disclose: (1) material, adverse facts concerning NowRx’s financial condition; (2) that NowRx was on the brink of bankruptcy or insolvency; (3) that NowRx had hired an investment bank to explore a sale or raise significant funds so that it could continue operations; (4) that as of December 31, 2021, NowRx was itself valued by an investment bank at $3.55 per share and this $3.55 per share price was significantly less than the $10.50 per share offering price in the Company’s Series C stock offering in 2022; and (5) as a result, investors in the Series C stock offering would likely lose their investment.
What’s Next for NowRx Investors?
A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911. If you suffered a loss in NowRx you have until January 23, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.
No Cost to NowRx Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for NowRx Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
window.addEventListener("load",function(){const urlParams=new URLSearchParams(window.location.search);const source=urlParams.get("utm_source")||"";const medium=urlParams.get("utm_medium")||"";const campaign=urlParams.get("utm_campaign")||"";const now=new Date();const timestamp=now.toISOString().replace("T"," ").split(".")[0];const iframe=document.querySelector("iframe[src*='jotform.com']");if(!iframe)return;const url=new URL(iframe.src);url.searchParams.set("utm_source",source);url.searchParams.set("utm_medium",medium);url.searchParams.set("utm_campaign",campaign);url.searchParams.set("timestamp",timestamp);iframe.src=url.toString()});
Key Dates
Dates are taken from the filed complaint and do not determine eligibility.
What Happens After You Contact Us?
Submit your information
Takes about a minute. Share count and statements are optional.
We review your transactions
Our team analyzes your trades against the class period at no cost.
We keep you updated
We'll contact you about your options and next steps.
Submitting information does not create an attorney-client relationship. You do not need to serve as lead plaintiff to share in any recovery.
How Is BG&G Representing Investors in Securities Class Actions?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."
Frequently Asked Questions
Who is eligible to join the NowRx class action?
Investors who purchased or otherwise acquired NowRx securities during the Class Period, February 1, 2022 – November 5, 2022, and suffered an overall net loss may be eligible to participate in a recovery. Eligibility depends on the class definition and your transaction history.
Do I need to be lead plaintiff to recover?
No. You do not need to serve as Lead Plaintiff to participate as a class member or share in a recovery. The Lead Plaintiff directs the litigation on behalf of the class, while other eligible class members are represented and may submit a claim if a settlement is reached.
I sold my shares — can I still participate?
Yes. Eligibility is generally based on when you purchased the shares and whether your overall investment resulted in a net loss, not on whether you still hold them. You may still be eligible even if you sold before the lawsuit was filed or before a settlement.
Does it cost anything to participate?
No. Securities class actions are handled on a contingency-fee basis. The law firms advance the litigation costs and are paid only if the case succeeds, subject to court approval. Class members do not pay legal fees directly.
What documents should I have ready?
Gather brokerage statements or trade confirmations showing your purchases, sales, transfers, and current holdings in the relevant security. Helpful details include transaction dates, share counts, prices, and the accounts in which the trades occurred.
What happens if I miss the January 23, 2026 deadline?
The January 23, 2026 deadline applies to seeking appointment as Lead Plaintiff. Missing it generally does not prevent an otherwise eligible investor from remaining a class member, filing a claim, or receiving a settlement share. Any later settlement claim deadline is separate and must still be followed.